Technical Analysis for IFRX - InflaRx N.V.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Hammer Candlestick | Bullish | -4.32% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.21% | |
Inside Day | Range Contraction | -2.21% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.21% | |
Doji - Bearish? | Reversal | -2.21% | |
Oversold Stochastic | Weakness | -2.21% | |
Spinning Top | Other | -2.92% | |
Lower Bollinger Band Walk | Weakness | -2.92% | |
Oversold Stochastic | Weakness | -2.92% |
Alert | Time |
---|---|
10 DMA Support | 2 days ago |
60 Minute Opening Range Breakdown | 2 days ago |
Down 5% | 2 days ago |
Down 3% | 2 days ago |
Fell Below 10 DMA | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Clinical Development Antibodies Autoimmune Disease Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.2 |
52 Week Low | 1.14 |
Average Volume | 233,797 |
200-Day Moving Average | 2.24 |
50-Day Moving Average | 1.54 |
20-Day Moving Average | 1.44 |
10-Day Moving Average | 1.34 |
Average True Range | 0.13 |
RSI (14) | 39.39 |
ADX | 11.41 |
+DI | 14.04 |
-DI | 16.62 |
Chandelier Exit (Long, 3 ATRs) | 1.28 |
Chandelier Exit (Short, 3 ATRs) | 1.64 |
Upper Bollinger Bands | 1.66 |
Lower Bollinger Band | 1.22 |
Percent B (%b) | 0.25 |
BandWidth | 30.20 |
MACD Line | -0.06 |
MACD Signal Line | -0.06 |
MACD Histogram | -0.0034 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.55 | ||||
Resistance 3 (R3) | 1.56 | 1.50 | 1.52 | ||
Resistance 2 (R2) | 1.50 | 1.44 | 1.49 | 1.50 | |
Resistance 1 (R1) | 1.41 | 1.40 | 1.38 | 1.40 | 1.49 |
Pivot Point | 1.35 | 1.35 | 1.33 | 1.34 | 1.35 |
Support 1 (S1) | 1.26 | 1.29 | 1.23 | 1.26 | 1.17 |
Support 2 (S2) | 1.20 | 1.25 | 1.19 | 1.16 | |
Support 3 (S3) | 1.11 | 1.20 | 1.14 | ||
Support 4 (S4) | 1.11 |